Recent progress in the construction and application of patient-derived pancreatic cancer organoid models

Hong CHEN; Zhiyun CAO

doi:10.19401/j.cnki.1007-3639.2024.06.007

您当前的位置：

首页 >

文章列表页 >

Recent progress in the construction and application of patient-derived pancreatic cancer organoid models

Review | 更新时间：2025-12-31

- Recent progress in the construction and application of patient-derived pancreatic cancer organoid models
- China Oncology Vol. 34, Issue 6, Pages: 590-597(2024)
- 作者机构：
  
  1. 福建中医药大学中西医结合研究院，福建福州 350122
  2. 福建省中西医结合老年性疾病重点实验室，福建福州 350122
  3. 福建省高校中西医结合基础重点实验室，福建福州 350122
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2024.06.007
  CLC： R735.9
- Received：03 January 2024，
  
  Revised：2024-04-11，
  
  Published：30 June 2024
- 稿件说明：
移动端阅览
Hong CHEN, Zhiyun CAO. Recent progress in the construction and application of patient-derived pancreatic cancer organoid models[J]. China Oncology, 2024, 34(6): 590-597.
DOI：

Hong CHEN, Zhiyun CAO. Recent progress in the construction and application of patient-derived pancreatic cancer organoid models[J]. China Oncology, 2024, 34(6): 590-597. DOI： 10.19401/j.cnki.1007-3639.2024.06.007.

摘要

胰腺癌严重威胁人类健康，其高度异质性和恶性表型使患者的5年生存率仅为7.2%。胰腺癌的发病机制及药物开发研究常依赖于传统的二维培养模型（细胞系）和患者来源异种移植瘤模型，但因细胞系缺乏肿瘤的三维环境和异质性特征，而异种移植瘤模型则存在培养时间长、成功率低、难以开展高通量药物筛选等问题，急需开发可高度反映胰腺癌特征和分子变异的三维培养模型。人源胰腺癌类器官作为近年发展起来的三维培养模型，是从组织样本中提取的多细胞单位，在机械和酶消化后嵌入细胞外基质凝胶中，可再现原患者的组织学特征及器官特点，甚至具有原器官的功能。随着胰腺癌类器官培养体系的不断发展及完善，其简便、经济及稳定的培养技术已经逐步建立，推动人源胰腺癌类器官的应用扩展到药物高通量筛选、个体化精准治疗、更深入的发病机制及针对性的药物开发研究。同时，人源胰腺癌类器官亦是胰腺癌临床分子分型研究的优势全新半体内模型，特别在针对研究高突变及高异质性患者的病因、分子特征、组织形态及体细胞突变负荷方面表现优越。大样本量人源胰腺癌类器官生物样本库的构建，将成为生物学、基础医学和临床肿瘤学研究的全新平台，有助于胰腺癌发病机制的深入研究及治疗策略的优化。人源胰腺癌类器官可再现临床患者特征的实验室模型的应用，将使药物筛选、发病机制研究、个体化治疗的实现成为可能。本文综述人源胰腺癌类器官的最新研究进展，希望该文为从事相关人源胰腺癌类器官研究的人员提供借鉴。

Abstract

Pancreatic cancer is a worldwide medical and health problem. Due to its high heterogeneity and malignant phenotype

the 5-year survival rate of pancreatic cancer is only 7.2%

which is a serious threat to human health. The biological mechanism and drug development research of pancreatic cancer often rely on the traditional two-dimensional culture models (cell lines) and patient-derived xenograft models. However

cell lines lack the three-dimensional environment and heterogeneity of the tumor

while xenograft models have the disadvantages of long culture time

low success rate and difficulty in carrying out high-throughput drug screening. There is an urgent need to develop three-dimensional culture models that can highly reflect the characteristics and molecular variation of pancreatic cancer. As a three-dimensional culture model developed in recent years

human-derived pancreatic cancer organoids are multicellular units extracted from tissue samples and embedded in extracellular matrix gels after mechanical and enzymatic digestion

which can reproduce the histological characteristics and organ characteristics of the original patient

and even have the functions of the original organ. With the continuous development and improvement of pancreatic cancer organoids culture system

its simple

economical and stable culture technology has been gradually established

which promotes the application of human pancreatic cancer organoids to high-throughput drug screening

individualized precision treatment and deeper pathogenesis and targeted drug development research. At the same time

human-derived pancreatic cancer organoids are also a novel semi-in vivo model for the study of clinical molecular typing of pancreatic cancer

especially for the study of etiology

molecular characteristics

histomorphology and somatic mutation burden of patients with high mutation rate and high heterogeneity. The construction of human pancreatic cancer organoid biobank with large sample size is a new platform for biology

basic medicine and clinical science oncology research

which provides a reliable resource for the in-depth study of the pathogenesis of pancreatic cancer and the development of treatment strategies. In summary

the research progress of human pancreatic cancer organoids promotes the application of laboratory models that recapitulate the characteristics of clinical patients

improves the connection between basic laboratory research and clinical patients

and provides clinical sources for drug screening

pathogenesis research

individualized treatment strategies and the construction of biobanks. Therefore

this article reviewed the latest research progress of human pancreatic cancer organoids

in order to provide reference for researchers engaged in the research of human pancreatic cancer organoids.

关键词

Keywords

references

SATO T , VRIES R G , SNIPPERT H J , et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche [J ] . Nature , 2009 , 459 ( 7244 ): 262 - 265 .

BOJ S F , HWANG C I , BAKER L A , et al. Organoid models of human and mouse ductal pancreatic cancer [J ] . Cell , 2015 , 160 ( 1/2 ): 324 - 338 .

BROUTIER L , MASTROGIOVANNI G , VERSTEGEN M M , et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening [J ] . Nat Med , 2017 , 23 ( 12 ): 1424 - 1435 . DOI: 10.1038/nm.4438 http://doi.org/10.1038/nm.4438

CHO J , LEE H , RAH W , et al. From engineered heart tissue to cardiac organoid [J ] . Theranostics , 2022 , 12 ( 6 ): 2758 - 2772 . DOI: 10.7150/thno.67661 http://doi.org/10.7150/thno.67661

KIM M , MUN H , SUNG C O , et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening [J ] . Nat Commun , 2019 , 10 ( 1 ): 3991.

SCHUTGENS F , ROOKMAAKER M B , MARGARITIS T , et al. Tubuloids derived from human adult kidney and urine for personalized disease modeling [J ] . Nat Biotechnol , 2019 , 37 ( 3 ): 303 - 313 . DOI: 10.1038/s41587-019-0048-8 http://doi.org/10.1038/s41587-019-0048-8

SALEWSKIJ K , PENNINGER J M . Blood vessel organoids for development and disease [J ] . Circ Res , 2023 , 132 ( 4 ): 498 - 510 . DOI: 10.1161/CIRCRESAHA.122.321768 http://doi.org/10.1161/CIRCRESAHA.122.321768

DENG J , ZHANG J , GAO K , et al. Human-induced pluripotent stem cell-derived cerebral organoid of leukoencephalopathy with vanishing white matter [J ] . CNS Neurosci Ther , 2023 , 29 ( 4 ): 1049 - 1066 . DOI: 10.1111/cns.14079 http://doi.org/10.1111/cns.14079

DA COSTA B L , LI Y , LEVI S R , et al. Generation of CRB1 RP patient-derived iPSCs and a CRISPR/Cas9-mediated homology-directed repair strategy for the CRB1 c.2480G>T mutation [J ] . Adv Exp Med Biol , 2023 , 1415 : 571 - 576 .

SAJJAD H , IMTIAZ S , NOOR T , et al. Cancer models in preclinical research: a chronicle review of advancement in effective cancer research [J ] . Animal Model Exp Med , 2021 , 4 ( 2 ): 87 - 103 . DOI: 10.1002/ame2.12165 http://doi.org/10.1002/ame2.12165

HUCH M , BONFANTI P , BOJ S F , et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis [J ] . EMBO J , 2013 , 32 ( 20 ): 2708 - 2721 .

GREGGIO C , FRANCESCHI F D , FIGUEIREDO-LARSEN M , et al. Artificial three-dimensional niches deconstruct pancreas development in vitro [J ] . Development , 2013 , 140 ( 21 ): 4452 - 4462 .

TIRIAC H , BUCOBO J C , TZIMAS D , et al. Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment [J ] . Gastrointest Endosc , 2018 , 87 ( 6 ): 1474 - 1480 . DOI: S0016-5107(18)30019-1 http://doi.org/S0016-5107(18)30019-1

CHOI W , KIM Y H , WOO S M , et al. Establishment of patient-derived organoids using ascitic or pleural fluid from cancer patients [J ] . Cancer Res Treat , 2023 , 55 ( 4 ): 1077 - 1086 . DOI: 10.4143/crt.2022.1630 http://doi.org/10.4143/crt.2022.1630

PISHVAIAN M J , BENDER R J , HALVERSON D , et al. Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative [J ] . Clin Cancer Res , 2018 , 24 ( 20 ): 5018 - 5027 . DOI: 10.1158/1078-0432.CCR-18-0531 http://doi.org/10.1158/1078-0432.CCR-18-0531

Cancer Genome Atlas Research Network Electronic Address: Andrew_Aguirre@Dfci Harvard Edu, Cancer Genome Atlas Research Network . Integrated genomic characterization of pancreatic ductal adenocarcinoma [J ] . Cancer Cell , 2017 , 32 ( 2 ): 185 - 203 .e13. DOI: S1535-6108(17)30299-4 http://doi.org/S1535-6108(17)30299-4

HE J , BLAIR A B , GROOT V P , et al. Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer? [J ] . Ann Surg , 2018 , 268 ( 1 ): 1 - 8 . DOI: 10.1097/SLA.0000000000002672 http://doi.org/10.1097/SLA.0000000000002672

SEPPÄLÄ T T , ZIMMERMAN J W , SERENI E , et al. Patient-derived organoid pharmacotyping is a clinically tractable strategy for precision medicine in pancreatic cancer [J ] . Ann Surg , 2020 , 272 ( 3 ): 427 - 435 .

VAES R D W , VAN DIJK D P J , WELBERS T T J , et al. Generation and initial characterization of novel tumour organoid models to study human pancreatic cancer-induced cachexia [J ] . J Cachexia Sarcopenia Muscle , 2020 , 11 ( 6 ): 1509 - 1524 . DOI: 10.1002/jcsm.12627 http://doi.org/10.1002/jcsm.12627

CHOI S H , PARK S H , KIM K W , et al. Progression of unresected intraductal papillary mucinous neoplasms of the pancreas to cancer: a systematic review and Meta-analysis [J ] . Clin Gastroenterol Hepatol , 2017 , 15 ( 10 ): 1509 - 1520 .e4.

ELTA G H , ENESTVEDT B K , SAUER B G , et al. ACG clinical guideline: diagnosis and management of pancreatic cysts [J ] . Am J Gastroenterol , 2018 , 113 ( 4 ): 464 - 479 . DOI: 10.1038/ajg.2018.14 http://doi.org/10.1038/ajg.2018.14

IDENO N , YAMAGUCHI H , GHOSH B , et al. GNASR201C induces pancreatic cystic neoplasms in mice that express activated Kras by inhibi ting YAP1 signaling [J ] . Gastroenterology , 2018 , 155 ( 5 ): 1593 - 1607 .e12.

KOPP J L , DUBOIS C L , SCHAEFFER D F , et al. Loss of pten and activation of Kras synergistically induce formation of intraductal papillary mucinous neoplasia from pancreatic ductal cells in mice [J ] . Gastroenterology , 2018 , 154 ( 5 ): 1509 - 1523 .e5.

BEATO F , REVERÓN D , DEZSI K B , et al. Establishing a living biobank of patient-derived organoids of intraductal papillary mucinous neoplasms of the pancreas [J ] . Lab Invest , 2021 , 101 ( 2 ): 204 - 217 . DOI: 10.1038/s41374-020-00494-1 http://doi.org/10.1038/s41374-020-00494-1

HUANG B , TRUJILLO M A , FUJIKURA K , et al. Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms [J ] . J Pathol , 2020 , 252 ( 3 ): 252 - 262 .

KATO H , TATEISHI K , FUJIWARA H , et al. MNX1-HNF1B axis is indispensable for intraductal papillary mucinous neoplasm lineages [J ] . Gastroenterology , 2022 , 162 ( 4 ): 1272 - 1287 .e16.

DESAI R , HUANG L , GONZALEZ R S , et al. Oncogenic GNAS uses PKA-dependent and independent mechanisms to induce cell proliferation in human pancreatic ductal and acinar organoids [J ] . Mol Cancer Res , 2024 , 22 ( 5 ): 440 - 451 .

ROMERO-CALVO I , WEBER C R , RAY M , et al. Human organoids share structural and genetic features with primary pancreatic adenocarcinoma tumors [J ] . Mol Cancer Res , 2019 , 17 ( 1 ): 70 - 83 .

GROSSMAN J E , MUTHUSWAMY L , HUANG L , et al. Organoid sensitivity correlates with therapeutic response in patients with pancreatic cancer [J ] . Clin Cancer Res , 2022 , 28 ( 4 ): 708 - 718 .

TIRIAC H , BELLEAU P , ENGLE D D , et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer [J ] . Cancer Discov , 2018 , 8 ( 9 ): 1112 - 1129 . DOI: 10.1158/2159-8290.CD-18-0349 http://doi.org/10.1158/2159-8290.CD-18-0349

FARSHADI E A , CHANG J , SAMPADI B , et al. Organoids derived from neoadjuvant FOLFIRINOX patients recapitulate therapy resistance in pancreatic ductal adenocarcinoma [J ] . Clin Cancer Res , 2021 , 27 ( 23 ): 6602 - 6612 . DOI: 10.1158/1078-0432.CCR-21-1681 http://doi.org/10.1158/1078-0432.CCR-21-1681

SHUKLA H D , DUKIC T , ROY S , et al. Pancreatic cancer derived 3D organoids as a clinical tool to evaluate the treatment response [J ] . Front Oncol , 2022 , 12 : 1072774 .

KOIKAWA K , KIBE S , SUIZU F , et al. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy [J ] . Cell , 2021 , 184 ( 18 ): 4753 - 4771 .e27. DOI: 10.1016/j.cell.2021.07.020 http://doi.org/10.1016/j.cell.2021.07.020

GRANAT L M , KAMBHAMPATI O , KLOSEK S , et al. The promises and challenges of patient-derived tumor organoids in drug development and precision oncology [J ] . Animal Model Exp Med , 2019 , 2 ( 3 ): 150 - 161 . DOI: 10.1002/ame2.12077 http://doi.org/10.1002/ame2.12077

ZHOU T X , XIE Y J , HOU X P , et al. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis [J ] . J Exp Clin Cancer Res , 2023 , 42 ( 1 ): 111.

SEINO T , KAWASAKI S , SHIMOKAWA M , et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression [J ] . Cell Stem Cell , 2018 , 22 ( 3 ): 454 - 467 .e6. DOI: S1934-5909(17)30510-6 http://doi.org/S1934-5909(17)30510-6

SEPPÄLÄ T T , ZIMMERMAN J W , SURI R , et al. Precision medicine in pancreatic cancer: patient-derived organoid pharmacotyping is a predictive biomarker of clinical treatment response [J ] . Clin Cancer Res , 2022 , 28 ( 15 ): 3296 - 3307 .

DEMYAN L , HABOWSKI A N , PLENKER D , et al. Pancreatic cancer patient-derived organoids can predict response to neoadjuvant chemotherapy [J ] . Ann Surg , 2022 , 276 ( 3 ): 450 - 462 . DOI: 10.1097/SLA.0000000000005558 http://doi.org/10.1097/SLA.0000000000005558

HIRT C K , BOOIJ T H , GROB L , et al. Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment [J ] . Cell Genom , 2022 , 2 ( 2 ): 100095.

DRIEHUIS E , GRACANIN A , VRIES R G J , et al. Establishment of pancreatic organoids from normal tissue and tumors [J ] . STAR Protoc , 2020 , 1 ( 3 ): 100192.

KUMANO K , NAKAHASHI H , LOUPHRASITTHIPHOL P , et al. Hypoxia at 3D organoid establishment selects essential subclones within heterogenous pancreatic cancer [J ] . Front Cell Dev Biol , 2024 , 12 : 1327772 .

KRIEGER T G , BLANC S L , JABS J , et al. Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy [J ] . Nat Commun , 2021 , 12 ( 1 ): 5826.

JABS J , ZICKGRAF F M , PARK J , et al. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations [J ] . Mol Syst Biol , 2017 , 13 ( 11 ): 955.

XU H X , LYU X D , YI M , et al. Organoid technology and applications in cancer research [J ] . J Hematol Oncol , 2018 , 11 ( 1 ): 116.

Views

2390

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A research on the mechanism of SERPINA3 promoting malignant progression and gemcitabine resistance of pancreatic cancer by inhibiting ferroptosis

Effect of liposome binding antisense oligonucleotide BP1003 on albumin-bound paclitaxel sensitivity in pancreatic cancer cells by inhibiting STAT3

New advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2024

An exploratory study of INPP4B, a biomarker of gemcitabine chemoresistance in pancreatic cancer

Application of organoids in drug screening of gynecological malignant tumors

Related Author

Yuan HE

Juncheng GUO

Zhibin YE

Xiaohu WANG

Haonan LI

Jingbiao HUANG

Hua FU

Guochao ZHOU

Related Institution

Department of Gastrointestial Surgery, Heping Hospital Affiliated to Changzhi Medical College

Department of Gastrointestial Surgery, Hebei General Hospital

The First Clinical College of Changzhi Medical College

Department of Hepatology and Gallbladder, Xiangxi Autonomous Prefecture People’s Hospital, Xiangxi

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai Pancreatic Cancer Institute, Shanghai Key Laboratory of Precision Medicine for Pancreatic Cancer, Pancreatic Cancer Institute, Fudan University

AI问答

⁰